• DCR . • PROs of pancreatic cancer symptoms. • Incidence of treatment-emergent AEs, SAEs , graded using the NCI CTCAE Version 4.03. Exploratory Endpoints: • Determination of tumor genomic, transcriptomic, and proteomic profiles and correl ations with subject outcomes. • Determination of PD-L1 expression from ct RNA and correlation with subject outcomes. Confidential and Proprietary 8 NANT Pancreatic Cancer Vaccine NantCell, Inc. Clinical Trial Protocol: QUILT -3.039 Enrollment (planned): In the phase 1b portion of the study, 6 to 24 subjects will be enrolled . In the phase 2 portion of the study, 23 subj ects will be enrolled in the first stage of Simon’s two -stage optimal design. If the study proceeds to the second stage of Simon’s two -stage optimal design, an additional 33 subjects will be enrolled in the second stage, for a total of 56 subjects in the phase 2 portion of the study. The maximum total enrollment will the study is 80 subjects. Diagnosis and Main Criteria for Inclusion: Inclusion Criteria: • Age ≥ 18 years old. • Able to understand and provide a signed informed consent that fulfills the relevant IRB or Independent Ethics Committee (IEC) guidelines. • Histologically -confirmed pancreatic cancer with progression on or after SoC therapy. • ECOG performance status of 0 to 2. • Have at least 1 measurable lesion and/or non -measurable disease evaluable acco rding to RECIST Version 1.1. • Must have a recent formalin -fixed, paraffin -embedded (FFPE) tumor biopsy specimen following the conclusion of the most recent anti -cancer treatment and be willing to release the specimen for tumor molecular profiling analysis. If an historic specimen is not available, the subject must be willing to undergo a biopsy during the screening period. • Must be willing to provide blood samples for exploratory analyses. • Ability to attend required study visits and return for adequate follow-up, as required by this protocol. • Agreement to practice effective contraception for female subjects with child -bearing potential and non-sterile males. Exclusion Criteria: • History of persistent grade 2 or higher (CTCAE Version 4.03) hematological toxici ty resulting from previous therapy. • History of other active malignancies or brain metastasis except: controlled basal cell carcinoma; prior history of in situ cancer (eg, breast, melanoma, cervical); prior history of prostate cancer that is not under active systemic treatment (except hormonal therapy) and with undetectable prostate- specific antigen (PSA ) (< 0.2 ng/mL); bulky (≥ 1.5 cm) disease with metastasis in the central hilar area of the chest and involving the pulmonary vasculature. Subjects with a history of another malignancy must have > 5 years without evidence of disease. • Serious uncontrolled concomitant disease that would contraindicate the use of the investigational drug used in this study or that would put the subject at high risk for treatment-related complications. Confidential and Proprietary 9 NANT Pancreatic Cancer Vaccine NantCell, Inc. Clinical Trial Protocol: QUILT -3.039 • Systemic autoimmune disease (eg, lupus erythematosus, rheumatoid arthritis, Addison's disease, autoimmune disease associated with lymphoma). • History of organ transplant requiring immunosuppression.